Company email18 Jun 2026 22:00
Glioblastoma Research Update:
Gallium Maltolate Phase 1 Results
We are pleased to announce the publication of results from the first-in-human Phase 1 clinical trial evaluating oral gallium maltolate (GaM) in patients with recurrent or treatment-refractory glioblastoma.
Key findings included:
GaM was well tolerated across daily doses ranging from 500 to 2,500 mg.
Treatment-related adverse events were limited to Grade 1–2 toxicities (primarily gastrointestinal/diarrhea), with no Grade ≥3 events observed.
No nephrotoxicity was observed.
The recommended Phase 2 dose was established at 2,000 mg daily.
Among 22 patients evaluable for tumor response, median overall survival was 16 months from the start of GaM treatment.
High proportion of extended survivors: 59% (13/22) of evaluable patients survived beyond 12 months, exceeding typical expectations in the recurrent setting.
One patient achieved a sustained partial response and remains on treatment (> 33 cycles at the time of publication).
As a small, nonrandomized Phase 1 dose-escalation trial, the study was not designed to establish efficacy. However, the findings support further evaluation of GaM in a statistically powered Phase 2 clinical trial.
Read the peer-reviewed publication in Neuro-Oncology Advances
The Phase 1 findings support the need for continued evaluation of gallium maltolate in recurrent glioblastoma through a statistically powered Phase 2 clinical trial.
Organizations interested in contributing to the next phase of clinical development are invited to contact Imaging Biometrics for additional information. eap@imagingbiometrics.com
Gallium maltolate remains investigational and has not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
Organizations interested in contributing to the next phase of clinical development are invited to contact Imaging Biometrics for additional information. eap@imagingbiometrics.com
Sign In
Follow the stocks
